Filaria specific antibody response profiling in plasma from anti-retroviral naive Loa loa microfilaraemic HIV-1 infected people by 諛뺤콈洹�
RESEARCH ARTICLE Open Access
Filaria specific antibody response profiling
in plasma from anti-retroviral naïve Loa loa
microfilaraemic HIV-1 infected people
Ghislain Donald Njambe Priso1,2, Abel Lissom1,2, Loveline N. NGU1,4, Nadesh N. Nji1, Jules Colince Tchadji1,2,
Thibau Flaurant Tchouangueu1,5, Georgia E. Ambada1,2, Carole Stéphanie Sake Ngane1,3,4, Brigitte Laure Dafeu1,2,
Larissa Djukouo1,4, Inès Nyebe1,3, Suzanne Magagoum1,2, Apeh Alfred Ngoh1,6, Ouambo Fotso Herve1,8,
Rosario Garcia7, Anna Gutiérrez7, Arinze S. Okoli12, Charles O. Esimone13, Flobert Njiokou2, Chae Gyu Park11,
Alain Bopda Waffo9,10 and Godwin W. Nchinda1*
Abstract
Background: In West and Central Africa areas of endemic Loa loa infections overlap with regions of high prevalence
of human immunodeficiency virus type 1 (HIV-1) infections. Because individuals in this region are exposed to filarial
parasites from birth, most HIV-1 infected individuals invariably also have a history of filarial parasite infection. Since HIV-
1 infection both depletes immune system and maintains it in perpetual inflammation, this can hamper Loa loa filarial
parasite mediated immune modulation, leading to enhanced loaisis.
Methods: In this study we have assessed in plasma from asymptomatic anti-retroviral (ARV) naïve Loa loa microfilaraemic
HIV-1 infected people the filarial antibody responses specific to a filariasis composite antigen consisting of Wbgp29-BmR1-
BmM14-WbSXP.
The antibody responses specific to the filariasis composite antigen was determined by enzyme linked immunosorbent
assay (ELISA) in plasma from ARV naïve Loa loa microfilaraemic HIV-1 infected participants. In addition the filarial antigen
specific IgG antibody subclass profiles were also determined for both HIV-1 positive and negative people.
Results: Both Loa loa microfilaraemic HIV-1 positive and negative individuals showed significantly higher plasma levels of
IgG1 (P < 0.0001), IgG2 (P < 0.0001) and IgM (P < 0.0001) relative to amicrofilaraemic participants. A significant increase in
IgE (P < 0.0001) was observed exclusively in Loa loa microfilaraemic HIV-1 infected people. In contrast there was
a significant reduction in the level of IgG4 (p < 0.0001) and IgG3 (P < 0.0001) in Loa loa microfilaraemic HIV-1
infected individuals.
Conclusions: Loa loa microfilaraemia in ARV naïve HIV-1 infected people through differential reduction of plasma
levels of filarial antigen specific IgG3, IgG4 and a significant increase in plasma levels of filarial antigen specific IgE
could diminish Loa loa mediated immune-regulation. This in effect can result to increase loaisis mediated
immunopathology in antiretroviral naive HIV-1 infected people.
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Background
Loa Loa, or the African eye worm, is a human filarial
parasite endemic in West and Central Africa, with over
13 million people currently infected with the parasite [1,
2]. During L. loa infection (Loiasis) the adult filarial
parasite can live in subcutaneous tissues for up 17 years
[3] and is capable of producing microfilariae (MF) in
peripheral blood which are the further transmitted by
the dipteran vector (chrysops spp). The great majority of
people infected with Loa loa show little or no visible
symptoms [4, 5]. This is because L. loa, like all helminth
infections, modulates immune responses to reach a safe
parasite-host equilibrium, where either high levels of loa
loa microfilaria (microfilaraemic loiasis) or no apparent
microfilaria (amicrofilaraemic loiasis) can be found in
peripheral blood [6, 7]. Some reports have suggested that
elevated levels of filarial parasite antigen specific IgG4
antibody subclass is essential for asymptomatic infection
[8]. But other reports have suggested that increased
expression of nonspecific polyclonal IgE [9] and elevated
levels of specific IgG4 [10] have been associated with
loaisis. Nevertheless all antibody isotypes, including IgM,
IgE and IgG, are known to play a major role in mediat-
ing protection to filarial infections [11].
In sub-Saharan Africa, areas of intense endemic
helminth infections overlap with regions of high preva-
lence of HIV-1 [12]. Therefore the risk of concomitant
infection with filarial parasites and HIV-1 is high. In
regions of high L. lao endemicity like Central and West
Africa with concurrent high HIV-1 prevalence, few
studies have looked at the interaction between these two
infections. Both L. loa and HIV-1 are chronic infections
where the pathogen can persist for longer periods in the
absence of sterilizing immunity. HIV-1 infection depletes
and maintains the immune system in a sustained inflam-
matory state, rendering the host more susceptible to
other infectious diseases. In contrast filarial parasites in
the majority of cases modulate the host’s immune re-
sponse to ensure their survival, thereby maintaining
asymptomatic infection with elevated plasma levels of
parasite antigen specific IgG4 [10]. This is generally as-
sociated with a generalized state of hypo-responsiveness
which ensures long term filarial parasite survival [11].
In this study, we have investigated the profile of filarial
antigen specific antibody responses of Loa loa microfi-
laraemic ARV naïve HIV-1 infected people in compari-
son with HIV-1 negative participants. This is because
filarial parasites employ both filarial antigen specific and
nonspecific immunomodulatory strategies to escape
elimination from the human host. However ARV naïve
HIV-1 infection depletes the immune system and with
concomitant persistent loa loa microfilaraemia the
profile of filarial antigen specific antibody responses is
not known. The immune depletion and sustained
inflammation associated with HIV-1 infection might
alter immune modulation and change the profile of filar-
ial antigen specific antibody responses in the context of
microfilaraemic loaisis. Thererfore, the profiles of filarial
antigen specific antibody responses in Loa loa microfi-
laraemic HIV-1 infected people could reveal possible in-
teractions between these two infections.
Using a mixture of four recombinant filarial parasite
antigens, consisting of Wbgp29, BmR1, BmM14 and
WbSXP, we have assessed antibody responses in both
microfilaraemic and amicrofilaraemic long standing
ARV naïve HIV-1 infected people in the CIRCB AFRO-
DEC cohort [13]. Antibody assays based on Bm14,
WbSXP, Wbgp29 or BmR1 have previously been demon-
strated to show excellent sensitivity (> 90%) in the detec-
tion of filarial specific antibodies [14, 15]. Bm14 and
WbSXP, for example, are highly reactive with their
respective antibodies in plasma from microfilaraemic in-
dividuals. More so prior studies have reported the Bm14
antibody test as a sensitive marker for infection or heavy
exposure to filarial parasites [14, 16, 17]. This implies
that this mixture of recombinant filarial antigen is suit-
able for assessing Loa loa specific antibody responses.
The consequence of ARV naïve HIV-1 infection was a
significant increase in plasma levels of filariasis compos-
ite antigen specific IgE. This was in association with a
significant decrease in serum levels of filarial antigen
specific IgG4 and IgG3, clearly suggesting a reduction in
Loa loa mediated immunomodulation.
Methods
Study population
Participants were 21 to 65 years old and samples were
collected as part of the CIRCB AFRODEC study. The
CIRCB AFRODEC (African HIV-1 dendritic cell targeted
vaccine) cohort study was conducted in Cameroon from
November 2012 to November 2016 and enrolled anti-
retroviral therapy (ARV) naïve HIV-1 infected people.
During the course of 4 years 199 participants out of the
766 members of CIRCB AFRODEC cohort who repeat-
edly complained of filarial infection were recruited for
this study. In addition confirmed 99 HIV-1 negative par-
ticipants complaining for microfilarae infecions were
also monitored alongside their HIV-1 positive counter-
parts as controls. Finally 25 Loa loa microfilaraemic
antiretroviral therapy (ARV) naïve HIV-1 infected partic-
ipants who remained Loa loa positive during the course
of 4 years were included in the analysis. 25 amicrofilar-
aemic ARV therapy naïve HIV-1 infected individuals
with no signs of loaisis were also included. Similarly a
control group of HIV-1 negative individuals was sepa-
rated into 25 Loa loa microfilaraemic and amicrofilarae-
mic participants. In addition to people who did not
provide consent, participants who had been diagnosed
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with Hepatitis B virus, Hepatitis C virus, Dengue virus,
Mycobacterium tuberculosis, or malaria were excluded
from the study. Absolute numbers of helper CD4+ T cells
for HIV-1 positive participants was determined in fresh
whole blood by BD multitest CD3/CD8/CD45/CD4 and
TruCount tubes (BD Biosciences, San Jose, USA) accord-
ing to the manufacturer’s instructions. Plasmatic HIV-1
viral load was determined on the m2000rt machine using
the Abbott Real-Time HIV-1 Assay protocol.
Study design (Fig. 1)
Members of the CIRCB AFRODEC cohort who are ei-
ther HIV-1 positive or negative, were included based on
the presence or absence of Loa loa microfilaraemia
during a period of 4 years. Recruited microfilaraemic
participants are those who showed at least two microfi-
laraemia per year during the period of the study.
Amicrofilaraemic participants were Loa loa negative
throughout the 4 years of the study.
Sample collection and processing
Blood was collected into 4-ml plastic vacuum blood
spray-coated K2EDTA tubes (Vacutestkirma, Italy). All
samples were stored at room temperature and processed
within 4 h of collection. To obtain plasma, samples were
centrifuged at 2000 rpm for 10 min at 4 °C. The plasma
fraction was harvested in sterile conditions under the
hood, aliquoted in small, single-use volumes and stored
at − 20 °C until use. All plasma obtained from anti-
retroviral naive HIV-1 infected participants was heat
inactivated for 30 min at 56 °C prior to ELISA assay.
Filarial diagnosis
Parasitological examination of individuals was done by
microscopic examination of 10% Giemsa stained periph-
eral blood (10 μl), both as thin and thick films. In the
CIRCB AFRODEC cohort screening for Loa loa microfi-
laraemia was performed three times annually for each
participant. Three independent confirmations of Loa loa
infection by different researchers were necessary for a
sample to be considered positive.
Enzyme linked immunosorbent assay (ELISA) for IgM, IgG
and IgE
Filariasis composite antigen Wbgp29-BmR1-BmM14-
WbSXP was diluted in PBS and 100 μl containing
100 ng/well were added to high binding 96-well flat bot-
tom microsorp (Thermo Fisher Scientific) ELISA plates
and incubated overnight at 4 °C. The following day,
plates were washed three times with PBST (PBS with 0.
05% Tween-20) and blocked either with 3% BSA or 1×
Roti block (Carl ROTH, Karlsruhe, Germany) for 1 hour
at 37 °C. After an additional washing step, 100 μl/well of
plasma diluted (1:500) in PBS was added into
Fig. 1 Study flow displaying screening and recruitment of study participants. Members of the CIRCB AFRODEC cohort which are either HIV-1 positive or
negative were included based on the presence or absence of Loa loa microfilaraemia during a period of 4 years. Recruited microfilaraemic participants are
those showed at least two microfilaraemia per year during the period of the study
Njambe Priso et al. BMC Infectious Diseases  (2018) 18:160 Page 3 of 11
corresponding wells in triplicates and incubated for 2
hours at 37 °C.
Next the plates are washed five times as described
above. Then 100 μl horseradish peroxidase (HRP)-conju-
gated anti-human IgG (1:2000) and horseradish peroxid-
ase (HRP)-conjugated anti-human IgG1, IgG2, IgG3,
IgG4, or IgM (1:4000) antibodies were added, and the
plates incubated for 1 h at 37 °C. Similarly for the detec-
tion IgE, HRP-conjugated anti-human IgE diluted 1:1000
was used. Antibody isotypes and subclasses used in this
study were mouse anti-human IgG Fc (clone JDC-10),
mouse anti-human IgM (clone UHB), mouse anti-
human IgE Fc (clone B3102E8), mouse anti-human IgG1
Fc (clone HP6001), mouse anti-human IgG2 Fc (clone
31-7-4), mouse anti-human IgG3 Hinge (clone HP6050)
and mouse anti-human IgG4 pFc’ (clone HP6023), all
HRP conjugate all procured from Southern Biotech®
(Birmingham, USA). Plates were then washed five times
and 100 μl of 2,2′-Azino-bis (3-ethylbenzthiazoline-6-
sulfonic acid) or ABTS one Component HRP substrate
was added to each well and incubated in the dark for
30 min. The enzyme substrate reaction was stopped by
adding a stop solution (Southern Biotech, Birmingha-
m,USA). The optical densities (OD) at 405 nm were read
using a multiscan Fc Elisa microplate reader (Thermo-
scientific, USA). All plasma was tested in triplicate and
the mean OD values were determined.
Statistics
Statistical analyses were done using the software
GraphPad PRISM version 6.0 (Graphpad Software).
Comparisons between groups were by the non-
parametric Mann-Whitney-U test (for paired data),
Student’s t-test (for unpaired data) and Kruskal-Wallis
test. Viral load was expressed on a log10 scale. P values
of 0.05 or less were considered significant.
Results
Study population
199 ARV naïve HIV-1 infected individuals from the
CIRCB AFRODEC cohort and 99 HIV-1 negative people
who repeatedly complained of filarial infection were
monitored for 4 years. During 4 years eligible
participants were separated into 4 groups based on their
HIV-1 status and persistent Loa loa microfilaraemia.
Excluded during the course of the study were individuals
diagnosed occasionally with Loa loa microfilaraemia,
Hepatitis B virus, Hepatitis C virus, Dengue virus,
Mycobacterium tuberculosis and malaria. Participants
retained for both HIV-1 positive and negative groups
based on persistent Loa loa microfilaraemia or amicrofi-
laraemia were analyzed. Amongst the HIV-1 infected
individuals, 25 were HIV-1 positive without microfilarae-
mia (HIV+/MF-) and 25 were Loa loa microfilaraemic
(HIV+/MF+). As shown in Table 1 for the HIV +MF-,
10 (40%) were males and 15 (60%) were females. Regard-
ing HIV +MF+ participants 09 (36%) were males and 16
(64%) were females respectively. In addition 25 microfi-
laraemia negative (HIV-/MF-) and 25 microfilaraemic
(HIV-/MF+) HIV-1 negative participants who were re-
peatedly tested as part of the CIRCB AFRODEC cohort
were analysed as controls. The age distribution between
the four different groups was similar (Table 1).
As shown in Table 1, microfilaria negative HIV-1 in-
fected participants differed significantly (p < 0.05) in
their median helper CD4+ T cell counts from
microfilaraemic HIV-1 infected people (compare 499
with 367.5 cells/mm3). In addition plasma viral load in
Loa loa microfilaraemic HIV-1 infected individuals was
significantly higher (P < 0.05) than in microfilaraemia
negative HIV-1 infected participants.
Loa loa microfilaraemia results in enhanced plasma levels
of Filariasis composite antigen specific IgM in both HIV-1
negative and positive individuals
When plasma levels of filariasis composite antigen spe-
cific IgM were considered both Loa loa microfilaraemic
HIV-1 negative (in Fig 2a compare HIV−/MF− with
HIV−/MF+) and positive (Fig 2b compare HIV+/MF−
with HIV+/MF+) individuals showed significantly higher
plasma levels (P < 0.001) vis a vis microfilaraemia
negative individuals (Fig 2 a & b). Loa loa
microfilaraemia in both HIV-1 positive and negative in-
dividuals was associated with significantly elevated OD
values of filariasis composite antigen specific IgM imply-
ing a continuous exposure to filarial antigens. The OD
Table 1 Study population characteristics
Variable HIV−/MF− (n = 25) HIV−/MF+ (n = 25) HIV+/MF− (n = 25) HIV+/MF+ (n = 25)
Gender Male and Female Male and Female Male Female Male Female
Participants (%) 8 (32) 17 (68) 11 (44) 14 (56) 10 (40) 15 (60) 9 (36) 16 (64)
Median Age (IQR) 34 (21-41) 49.50 (45.25-55.25) 34 (32-43.50) 37 (27-46) 38 (28-46) 35.5 (28.75-45)
Mf count (MF/ml) Median N/A 1800 (10-4800) N/A 986.7 (1-3200)
Median CD4 counts (cells/mm3) N/A N/A 499 (IQR 310.5-886.8) 367.5 (IQR 157.8-460.8) *
Median Viral load (Log10 copies/ml) N/A N/A 3.05 (IQR 1.76-3.85) 5.04 (IQR 4.530-5.5)
*
*P < 0.05, N/A = Not Applicable, IQR = interquartile range, ns = not significant, MF+ =microfilaria positive
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values showed a slight negative correlation with the
microfilaria burden (r = − 0.084 data not shown). In Fig 2c
a statistical analysis is shown for the four different groups
with respect to plasma levels of filariasis composite
antigen specific IgM. When HIV-1 positive and negative
individuals were compared, except for a slight reduction
in the plasma level of antigen specific IgM of Loa loa
microfilaraemic ARV naïve HIV-1 infected people there
was no significant difference in plasma level of filariasis
antigen specific IgM in both microfilaraemia HIV-1 posi-
tive and negative individuals (Fig 2c). Thus elevated
plasma levels of filarial antigen specific IgM are associated
with Loa loa microfilaraemia in both HIV-1 negative and
positive people.
ARV naïve HIV-1 infections results in elevated plasma levels
of filariasis composite antigen specific IgE exclusively in
Loa loa microfilaraemic individuals
A unique situation was observed with plasma levels of
filariasis composite antigen specific IgE where signifi-
cantly (P < 0.0001) elevated plasma levels of antigen
specific IgE was observed exclusively for Loa loa micro-
filaraemic ARV naïve HIV-1 infected people. In contrast
little or no antigen specific IgE was detected in the other
three groups (compare Fig. 3 a&b). In Fig. 3c a statistical
analysis is shown for the four different groups with re-
spect to plasma levels of filariasis antigen specific IgE.
Thus ARV naïve HIV-1 infection escalates plasma levels
of filariasis antigen specific IgE, which could result in an
increase in immunopathology.
Filariasis composite antigen specific IgG antibody
responses in Loa loa microfilaraemic antiretroviral naïve
HIV-1 infected individuals
With respect to plasma levels of filariasis composite
antigen specific IgG; Loa loa microfilaraemic HIV-1
negative individuals showed significantly higher levels (P
< 0.01) relative to amicrofilaraemia individuals (in Fig. 4a
compare HIV−/MF− with HIV−/MF+). Plasma levels of
filariasis composite antigen specific IgG in ARV naïve
HIV-1 infected participants in contrast did not differ sig-
nificantly between Loa loa microfilaraemia positive and
negative individuals (Fig. 4b compare HIV+/MF− with
HIV+/MF+).
In Fig 4c a statistical analysis is shown for the four dif-
ferent groups with respect to plasma levels of filariasis
Fig. 2 Plasma levels of Filariasis composite antigen specific IgM in Loa loa microfilaraemia positive and negative ARV naïve HIV-1 infected people
compared to seronegative people. As shown in (a) & (b) loa loa microfilaraemia results in significantly (P < 0.001) higher plasma levels of IgM in
both HIV-1 negative and positive individuals (compare HIV−/MF+ with HIV+/MF+). In (c) a comparative statistically analysis is made between the
four groups with respect to plasma levels of their Filariasis composite antigen specific IgM. In (c) a slight but insignificant reduction (P < 0.115) is
observed in plasma levels of antigen specific IgM in Loa loa microfilaraemic ARV naïve HIV infected people. Statistical analysis was done with prism
graph path 6.0, unpaired t test, Mann-Whitney-U tests and Kruskal-Wallis test
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composite antigen specific IgG. During this study ARV
naïve HIV-1 infected people generally demonstrated sig-
nificantly higher plasma levels (P < 0.001) of filariasis com-
posite antigen specific IgG relative to HIV negative
individuals irrespective of Loa loa microfilaraemia. In this
case when microfilaraemia negative seronegative individ-
uals are compared with ARV naïve HIV-1 infected people
a significantly higher plasma level of filariasis antigen spe-
cific IgG was observed for the HIV-1 infected people (Fig.
4c). Increased filariasis specific IgG levels in ARV naïve
HIV-1 infected people could be an indication of the ab-
sence of effective immunodulation which is relevant in the
long term survival of microfilaria. This in effect could es-
calate filarial parasite mediated immunopathology.
Increased plasma levels of Filariasis composite antigen
specific IgG1 and IgG2 antibody subclass responses in
Loa loa microfilaraemic individuals
The plasma level of filariasis composite antigen specific
IgG1 was significantly (P < 0.0001) elevated during Loa loa
microfilaraemia in both HIV-1 positive and negative indi-
viduals (Fig. 5a&b). In Fig. 5c a statistical analysis is shown
for the four different groups with respect to plasma levels
of filariasis composite antigen specific IgG1. When
participants were compared with respect to HIV-1 status
a significant increase in plasma level of IgG1 was observed
in microfilaraemia negative ARV naïve HIV-1 infected in-
dividuals relative to seronegative individuals. In contrast
when microfilaraemic HIV-1 positive and negative individ-
uals were compared a significant reduction (P < 0.05) in
IgG1 was observed in ARV naïve HIV-1 infected partici-
pants (Fig. 5c). This implies that Loa loa microfilaraemic
ARV naïve HIV-1 infection can lead to a significant reduc-
tion in plasma levels of filariasis composite antigen spe-
cific IgG1.Similarly Loa loa microfilaraemia resulted in
elevated plasma levels of IgG2 in both HIV-1 positive and
negative individuals (Fig. 5d&e). When HIV-1 infected
people were compared with their negative counter parts
no significant difference (P < 0.2) was observed between
microfilaraemic HIV-1 positive and negative people with
respect to plasma levels of filariasis composite antigen
specific IgG2 (Fig. 5f).
Reduction in plasma levels of Filariasis composite antigen
specific IgG3 and IgG4 antibody subclass responses in Loa
loa microfilaraemic ARV naïve HIV-1 infected individuals
Plasma level of filariasis composite antigen specific IgG3
was significantly (P < 0.0001) higher in Loa loa
Fig. 3 Plasma levels of Filariasis composite antigen specific IgE in Loa loa microfilaraemia positive and negative ARV naïve HIV-1 infected people
compared to seronegative people. As shown in (a) & (b) Loa loa microfilaraemia results in significantly (P < 0.001) higher plasma levels of antigen
specific IgE exclusively in ARV naïve HIV-1 infection (compare HIV−/MF+ with HIV+/MF+). In (c) a comparative statistically analysis is made between
the four groups with respect to plasma levels of their Filariasis composite antigen specific IgE. In (c) a significantly higher (P < 0.0001) plasma
levels of antigen specific IgE is observed exclusively in Loa loa microfilaraemic ARV naïve HIV infected people. Statistical analysis was done with
prism graph path 6.0, unpaired t test, Mann-Whitney-U test and Kruskal-Wallis test
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microfilaraemic HIV-1 negative individuals (Fig. 6a). In
contrast in ARV naïve HIV-1 infected people there was
a significant reduction in plasma levels of filariasis com-
posite antigen specific IgG3 (Fig. 6b). In Fig. 6c a statis-
tical analysis is shown for the four different groups with
respect to plasma levels of filariasis composite antigen
specific IgG3. When participants were next compared
with respect to HIV-1 status a significant reduction in
plasma level of IgG3 was associated with microfilaraemic
ARV naïve HIV-1 infection. This was in contrast to
microfilaraemia negative individuals where significantly
high plasma levels of filariasis composite antigen specific
IgG3 was observed in ARV naïve HIV-1 infected individ-
uals (Fig. 6c). On the other hand filariasis composite
antigen specific IgG4 Plasma levels were reduced signifi-
cantly (P < 0.0001) in Loa loa microfilaraemic HIV-1 in-
fected individuals compared to microfilaraemia negative
HIV-1 positive people. In addition microfilaraemia nega-
tive HIV-1 infected people showed comparatively similar
filariasis composite antigen specific IgG4 Plasma levels
like Loa loa microfilaraemic HIV-1 negative individuals.
(Fig. 6 d&e). In Fig. 6f a statistical analysis is shown for
the four different groups with respect to plasma levels of
antigen specific IgG4. Comparing HIV-1 negative with
positive individuals filariasis composite antigen specific
IgG4 Plasma levels were generally higher in ARV naïve
HIV-1 positive than negative.
Discussion
In this study we have assessed the impact of ARV naïve
HIV-1 infection on the patterns of filariasis composite
antigen specific antibody responses in microfilaremic
loaisis by analyzing plasma profiles of filariasis compos-
ite antigen specific IgG, IgM and IgE amongst HIV-1
positive and negative participants. This is mainly because
filairial antigen specific IgG, IgE and IgM have been
demonstrated to play critical roles in acquired immunity
to filarial parasite infection [18]. However in the context
of microfilaraemia in ARV naïve HIV-1 infection where
there is not only HIV-1 driven immune depletion but
equally sustained inflammation little is known about the
profiles of filarial antigen specific antibody responses.
The need for this study becomes pertinent especially
with recent reports indicating that the hitherto relatively
less pathogenic loaisis [4, 5] can be a significant cause of
mortality in Loa loa endemic countries [19]. Two main
groups consisting of ARV naïve HIV-1 infected members
of the CIRCB AFRODEC cohort and HIV-1 negative
Fig. 4 Plasma levels of Filariasis composite antigen specific IgG in Loa loa microfilaraemia positive and negative ARV naïve HIV-1 infected people
compared to seronegative people. As shown in (a) & (b) Loa loa microfilaraemia results in significantly (P < 0.001) higher plasma levels of antigen
specific IgG exclusively in HIV-1 negative individuals (compare HIV-/MF- with HIV-/MF+). In (c) a comparative statistically analysis is made between
the four groups with respect to plasma levels of their Filariasis composite antigen specific IgG. Statistical analysis was done with prism graph path
6.0, unpaired t test Mann-Whitney-U tests and Kruskal-Wallis test
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participants were used for this study. The ARV naïve
HIV-1 infected group was further split into Loa loa micro-
filaraemia positive (HIV+MF+) and negative (HIV+MF−)
individuals respectively. Similarly the HIV-1 negative
group consisted of microfilaraemia (HIV−MF+) positive
and negative (HIV−MF−) individuals. All participants were
members of the CIRCB AFRODEC cohort for the last 4
years and were repeatedly monitored for Loa loa
microfilaraemia during this period.
Using a filariasis composite antigen consisting of
Wbgp29-BmR1-BmM14-WbSXP in ELISA assay differ-
ences in filarial antigen specific antibody responses be-
tween the four subgroups was analyzed based on the
presence or absence of microfilariae. Our study revealed
significantly elevated plasma levels of filariasis composite
antigen specific IgG1, IgG2 and IgM in plasma from
both microfilaraemic ARV naïve HIV-1 positive and
negative participants. These findings agree with previous
studies which linked elevated levels of filarial antigen
specific IgG1 and IgG2 with the presence of microfilar-
iae [20]. The HIV-1 infection status had a significant
effect on the plasma level of filariasis composite antigen
specific IgE, IgG3 and IgG4 in Loa loa microfilaraemic in-
dividuals. Thus, while in HIV-1 negative people Loa loa
microfilaraemia resulted to a significant increase in plasma
levels of filarial antigen specific IgM, IgG, IgG1, IgG2,
IgG3 and IgG4, it produced a completely different out-
come in ARV naïve HIV-1 infected people. In this case
apart from IgG1 and IgG2 plasma levels of filariasis com-
posite antigen specific IgG3 and IgG4 were significantly
decreased in microfilaraemic ARV naïve HIV-1 infection.
In addition microfilaraemic ARV naïve HIV-1 infected
people also showed an exclusive increased in plasma levels
of filarial antigen specific IgE which was significantly
higher than all the groups described in this study.
Microfilaraemia during lymphatic filariasis has been
linked to elevated levels of species specific IgG4 [21, 22].
Previous studies have shown that Loa loa specific IgG4
was elevated in both microfilaraemic and amicrofilarae-
mic persons [9, 10, 23]. However using the filariasis
composite antigen assay we detected significantly higher
plasma levels of antigen specific IgG4 in microfilaraemic
HIV-1 negative people relative to their HIV-1 positive
counterparts. This agrees with previous observation in-
dicating that microfilariae were the main inducers of
IgG4 [24]. In this context elevated levels of filarial
antigen specific IgG4 have been incriminated in immu-
nomodulation which is necessary for the filarial parasite
to evade immune destruction [9, 25–27].
The significant reduction in plasma levels of IgG4 in Loa
loa microfilaraemic HIV-1 infected people is probably due
to immune depletion resulting from the ARV naïve HIV-1
Fig. 5 Plasma levels of Filariasis composite antigen specific IgG1 and IgG2 in Loa loa microfilaraemia positive and negative ARV naïve HIV-1 infected people
compared to seronegative people. As shown in (a, b&c) Loa loa microfilaraemia results to significantly (P < 0.001) higher plasma levels of antigen specific
IgG1 in both HIV-1 negative and positive individuals (compare HIV-/MF- with HIV-/MF+). Similarly in (D, E &F) Loa loa microfilaraemia results to significantly
(P < 0.001) higher plasma levels of antigen specific IgG2 in both HIV-1 negative and positive individuals (compare HIV−/MF− with HIV−/MF+). Statistical
analysis was done with prism graph path 6.0, unpaired t test, Mann-Whitney-U tests and KruskalKruskal-Wallis test
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infection. This implies that the reduction in plasma levels
of filarial antigen specific IgG4 mediated by ARV naïve
HIV-1 infection even in the presence of microfilariae could
potentially exacerbate Loa loa filarial mediated immunopa-
thology. This is especially so as the decrease in filarial anti-
gen specific IgG4 was accompanied in microfilaraemic
HIV-1 positive people by a significant increase in plasma
levels of filarial antigen specific IgE. Several reports suggest
that the rate of induction, magnitude and the ratio between,
the IgE and IgG4 isotypes are major determinants of the
clinical outcomes of lymphatic filariasis. In this way, pa-
tients with chronic lymphatic disease have been reported
with elevated ratios of filarial antigen specific IgE to IgG4.
This was in contrast to asymptomatic microfilaraemic pa-
tients who presented high plasma levels of IgG4 with a cor-
responding low IgE to IgG4 ratio. [22, 28–31]. This implies
that in microflaraemic ARV naïve HIV-1 infected people
the significantly high plasma levels of filarial antigen spe-
cific IgE accompanied with reduced specific IgG4 could be
an indication of increased immunopathology. Compared to
microfilaria negative HIV-1 positive individuals there was
enhanced immune depletion in Loa loa microfilaraemic
ARV naïve HIV-1 infected people. Here Loa loa
microfilaraemic ARV naïve HIV-1 infection also resulted in
a significant increase in plasma viral load. A two log in-
creased in viral load relative to microfilaria negative partici-
pant is a clear indication that dual chronic Loa loa
microfilaraemia and HIV-1 infection can escalate the ex-
pansion of the virus. Thus in depleting the immune system
ARV naïve HIV-1 infection can differentially influence anti-
filarial antigen specific IgE, Ig3 and IgG4 in microfilaraemic
loaisis. On the other hand Loa loa microfilaraemia can es-
calate immune depletion in HIV-1 infection and signifi-
cantly influence HIV-1 viral load. This bidirectional effect
of Loa loa microfilaraemia and ARV naïve HIV-1 infection
on each other can escalate morbidity and mortality.
Conclusions
Thus Loa loa microfilaraemia in ARV naïve HIV-1 in-
fected people, through differential reduction of plasma
levels of filarial antigen specific IgG3, IgG4 and a signifi-
cant increase in plasma levels of filarial antigen specific
IgE, could diminish Loa loa mediated immune-
regulation. This can result in an increase in loaisis medi-
ated immunopathology in antiretroviral naive HIV-1
infected people.
Fig. 6 Plasma levels of Filariasis composite antigen specific IgG3 and IgG4 in Loa loa microfilaraemia positive and negative ARV naïve HIV-1 infected
people compared to seronegative people. As shown in (a) Loa loa microfilaraemia results to significantly (P < 0.0001) elevated plasma levels of antigen
specific IgG3 in HIV-1 negative people on the one hand and a significant reduction (P < 0.0001) of antigen specific IgG3 in HIV-1 positive individuals on
the other hand. Similarly in (e) Loa loa microfilaraemia results to significantly (P < 0.0001) higher plasma levels of antigen specific IgG4 in HIV-1 negative
individuals in contrast to a significant reduction (P < 0.001) in HIV-1 positive individuals (compare HIV-/MF- with HIV-/MF+). Here the effect of Loa loa
microfilaraemic HIV-1 infection was a significant reduction in plasma levels of filariasis composite antigen specific IgG3 (P < 0.0001) and IgG4 (P < 0.001).
Statistical analysis was done with prism graph path 6.0, unpaired t test, Mann-Whitney-U tests and Kruskal-Wallis test
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